| Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega. | |
| | |
MedLine Citation:
|
PMID: 18196745 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Recombinant feline interferon-omega (rFeIFN-omega) was tested as a treatment option for cats with fibrosarcoma to assess safety and feasibility. HYPOTHESIS: Treatment with rFeIFN-omega in cats with fibrosarcoma is safe and feasible. ANIMALS: Twenty domestic cats. METHODS: In an open-labeled uncontrolled clinical trial 12 injections of 1 x 10(6) U/kg rFeIFN-omega were administered over a 5-week period: the 1st through 4th injections were given intratumorally, and the 5th through 12th injections were administered subcutaneously at the tumor excision site. Wide surgical excision of the tumors was carried out after the 4th injection and before the 5th injection of rFeIFN-omega. A Common Terminology Criteria for Adverse Events (CTCAE) analysis was conducted. Flow cytometry of fibrosarcoma cells after incubation with rFeIFN-omega and recombinant feline interferon-gamma was performed to assess the biological effect of rFeIFN-omega. RESULTS: Changes in blood cell count, increases in serum aspartate-amino-transferase activity, serum bilirubin concentration, serum creatinine and serum electrolyte concentrations, weight loss, anorexia, increased body temperature, and reduced general condition were observed but were mostly minor (grade 1 and 2) and self limiting. Eosinophilia (P = .025), neutropenia (P = .021), and weight loss (P < .001) were statistically correlated with rFeIFN-omega-treatment (analysis of parameters before treatment and after 3 injections of rFeIFN-omega). Flow cytometry of 5 unrelated feline fibrosarcoma cell lines showed increased expression of major histocompatibility complex (MHC) class I molecules (P = .026) in response to in vitro incubation with rFeIFN-omega, whereas expression of MHC class II molecules was not affected significantly. CONCLUSIONS AND CLINICAL IMPORTANCE: RFeIFN-omega for the treatment of feline fibrosarcoma is safe, well tolerated, and can be easily performed in practice. To assess the efficacy of the treatment, it should be tested in a placebo-controlled trial. |
| | |
Authors:
|
Verena Hampel; Bianca Schwarz; Christine Kempf; Roberto Köstlin; Ulrike Schillinger; Helmut Küchenhoff; Nora Fenske; Thomas Brill; Johannes Hirschberger |
Related Documents
:
|
7804355 - Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bea... 10505855 - Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fi... 9475665 - Effect of ifn-alpha on tumor-infiltrating mononuclear cells and regressive changes in m... 19950185 - Requirements for control of b-cell lymphoma by nk cells. 23603885 - Awake craniotomy for brain tumor resection: the rule rather than the exception? 17200345 - Clonal and parallel evolution of primary lung cancers and their metastases revealed by ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of veterinary internal medicine / American College of Veterinary Internal Medicine Volume: 21 ISSN: 0891-6640 ISO Abbreviation: J. Vet. Intern. Med. Publication Date: 2007 Nov-Dec |
Date Detail:
|
Created Date: 2008-01-16 Completed Date: 2008-02-14 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8708660 Medline TA: J Vet Intern Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1340-6 Citation Subset: IM |
Affiliation:
|
Department of Veterinary Internal Medicine, Veterinary Faculty, LMU Munich, Munich, Germany. verena.hampel@web.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
therapeutic use* Animals Cat Diseases / drug therapy* Cats Fibrosarcoma / drug therapy, veterinary* Histocompatibility Antigens Interferon Type I / therapeutic use* Interferon-gamma / therapeutic use Recombinant Proteins |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Histocompatibility Antigens; 0/Interferon Type I; 0/Recombinant Proteins; 0/interferon omega 1; 82115-62-6/Interferon-gamma |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in do...
Next Document: Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal ...